Amgen Inc. $AMGN Position Lifted by IFP Advisors Inc

IFP Advisors Inc raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 478.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 47,499 shares of the medical research company’s stock after acquiring an additional 39,283 shares during the period. IFP Advisors Inc’s holdings in Amgen were worth $20,021,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. MW Advisory LLC bought a new stake in Amgen during the second quarter valued at $1,054,000. Baird Financial Group Inc. raised its holdings in shares of Amgen by 1.6% during the second quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock worth $123,057,000 after purchasing an additional 5,496 shares during the period. Integrated Advisors Network LLC raised its holdings in shares of Amgen by 50.5% during the first quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company’s stock worth $6,664,000 after purchasing an additional 6,356 shares during the period. KBC Group NV lifted its position in shares of Amgen by 51.7% in the 2nd quarter. KBC Group NV now owns 382,676 shares of the medical research company’s stock worth $138,574,000 after buying an additional 130,497 shares during the last quarter. Finally, Nilsine Partners LLC bought a new position in shares of Amgen in the 2nd quarter worth about $3,329,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Down 0.4%

AMGN stock opened at $432.49 on Friday. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. Amgen Inc. has a fifty-two week low of $288.00 and a fifty-two week high of $447.03. The firm’s 50-day simple moving average is $415.54 and its 200 day simple moving average is $374.76. The stock has a market cap of $233.82 billion, a PE ratio of 26.88, a price-to-earnings-growth ratio of 3.17 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. Amgen’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period last year, the firm posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts predict that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s payout ratio is 62.65%.

Insider Activity at Amgen

In other news, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the completion of the transaction, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Nancy Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 6,222 shares of company stock valued at $2,540,926. Insiders own 0.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on AMGN shares. Barclays lifted their price target on shares of Amgen from $360.00 to $380.00 and gave the company an “equal weight” rating in a report on Friday, August 14th. Royal Bank Of Canada increased their price objective on shares of Amgen from $400.00 to $430.00 and gave the stock an “outperform” rating in a research note on Thursday, October 8th. TD Cowen raised their target price on shares of Amgen from $420.00 to $452.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Jefferies Financial Group reissued a “hold” rating and issued a $410.00 target price on shares of Amgen in a report on Wednesday, September 23rd. Finally, Wells Fargo & Company decreased their target price on Amgen from $435.00 to $430.00 and set an “equal weight” rating for the company in a research note on Monday, October 12th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $387.93.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.